2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 252-254
Technology and Procedures, Assays, Treatment Considerations, Biological Processes, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human
PAPER

13 Clinical and laboratory predictors of kidney function decline in sickle cell disease: ASH research collaborative data hub analysis

Santosh L Saraf, MD, Julia Seaman2, Jeffrey Lebensburger, DO3, Kenneth I Ataga, MD4, Vimal K. Derebail, MD, MPH5, Kirk Campbell, MD6, Claire C Sharpe, MD7, Rima Zahr, DO, MS8, ISABEL ELAINE ALLEN, PhD9, Emily Semmel, MS10, Alain Romero, PharmD, PhD11
1 University of Illinois Chicago, Chicago, Illinois, United States
2 Bay View Analytics, Oakland, California, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Tennessee Health Science Center, Memphis, United States
5 University of North Carolina, Chapel Hill, North Carolina, United States
6 University of Pennsylvania, Philadelphia, United States
7 University of Nottingham, Nottingham, United Kingdom
8 University of Tennessee Health Science Center, Memphis, Tennessee, United States
9 Bay View Analytics, Oakland, California, United States
10 American Society of Hematology, Washington, District of Columbia, United States
11 Kidney Health Initiative, Washington, District of Columbia, United States

Introduction: Chronic kidney disease (CKD) develops in up to 40% of patients with sickle cell disease (SCD) and leads to substantial morbidity and early mortality. Despite the well-recognized burden of SCD-related CKD, there is limited clinical data on risk factors for a more rapid decline in kidney function as well as on the efficacy of therapies to mitigate kidney damage. Hydroxyurea (HU), is an SCD modifying therapy that reduces the incidence of acute vaso-occlusive episodes and is considered standard of care for managing patients with SCD-related complications. However, clinical data on the efficacy of HU on preserving or improving kidney function in SCD is limited to small cohorts with short follow up. The purpose of this study was to investigate laboratory and clinical variables associated with a more rapid decline in kidney function and the long-term effects of HU on kidney function in a large, real-world cohort of patients with SCD.

Methods: We investigated longitudinal kidney function changes in 10,473 patients with SCD, more than half treated with HU, in the multicenter ASH Research Collaborative (ASH RC) Data Hub. We selected this cohort based upon a physician-attested diagnosis of SCD and at least 2 serum creatinine values over ≥1 year of follow up and data were censored on 9/30/2025 (range 1/12/1996–9/30/2025). Treatments were fit separately into linear or logistic models adjusting for age, sex, hemoglobin [Hb] SS or Sβ0-thalassemia subtype and baseline urine albumin-to-creatinine ratio (uACR) or estimated glomerular filtration rate (eGFR) for uACR and eGFR slope analyses, respectively. The uACR was log transformed for the linear regression analyses. The eGFR was calculated using the modified Full Age Spectrum equation. We evaluated the change in kidney function based on ever using HU as well as cumulative treatment duration (greater or equal to 1- and 2-years of use) during the observation period. Mean ± standard error values are provided.

Results:  The median age of the analyzed cohort, the largest to date, was 15.1 (interquartile range [IQR] 3.5-27.7) years, 53% were female, 67% were Hb SS/Sβ0-thalassemia subtype, and the median follow up was 9.28 (IQR, 6.54-11.88) years. The mean annual rate of eGFR decline in the entire cohort was -0.58±0.05 mL/min/1.73m2 and was accelerated with older age (β -0.05±0.003). Other clinical and laboratory variables associated with a more rapid rate of eGFR decline included a lower hemoglobin (β -0.33±0.06) and higher serum ferritin concentration (log-transformed β -0.35±0.06) and diagnoses of hypertension (β -0.81±0.13), pulmonary hypertension (β -1.34±0.16), or diabetes mellitus (β -0.63±0.18), adjusting for age, sex, Hb SS or Sβ0-thalassemia subtype, and baseline eGFR (P<0.001). The mean annual rate of uACR change was +0.77±4.92 mg/g.

HU was ever used by 6,229 (59.5%) of patients in the cohort and associated with an improved rate of eGFR decline. Hydroxyurea use for ≥1 year (n = 4,688; β +0.45±0.12; P<0.001) and for ≥2 years (n =3,836 ; β +0.41±0.12; P<0.001) was independently associated with improved rates of eGFR decline after adjusting for age, sex, Hb SS or Sβ0-thalassemia subtype, and baseline eGFR. We observed nonsignificant effects of HU on uACR slope at these respective time points. In age-stratified analysis, the eGFR benefit of HU was driven by adults (≥1 year use, β +0.46±0.16; P=0.005) and was not significant in children. Treatment-by-SCD subtype interaction was not significant.

Discussion: In conclusion, this large, multicenter EHR cohort provides a substantial real-world evidence base for investigating long-term kidney treatment effects. In this cohort, a lower hemoglobin concentration and pulmonary hypertension were associated with a more rapid decline in eGFR supporting the pathophysiologic role for hemolytic anemia in SCD-related CKD. Hypertension and diabetes mellitus are major causes of CKD in the general population. Both comorbidities were associated with a more rapid decline in eGFR in this ASH RC Data Hub analysis, emphasizing the need for screening and treating these comorbidities in patients with SCD. Within this cohort, longer HU exposure was associated with slower eGFR decline. The renoprotective effects of HU could include improving hemolytic anemia and/or a reduction in vaso-occlusive episodes leading to acute kidney injury. Further investigation into these associations and other SCD or CKD treatments will continue for this cohort.

Santosh L Saraf, MD: Novartis - Research Funding; Pfizer - Research Funding; Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BEAM Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Chiesi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)